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Background: Inadequate blood pressure (BP) control is a frequent challenge in general practice. 
The objective of this study was to determine whether a color-coded BP booklet using a traffic light 
scheme (red, 180 mmHg systolic BP and/or 110 mmHg diastolic BP; yellow, 140–180 mmHg 
systolic BP or 90–110 mmHg diastolic BP; green, 140 mmHg systolic BP and 90 mmHg 
diastolic BP) improves BP control and adherence with home BP measurement.
Methods: In this two-group, randomized controlled trial, general practitioners recruited adult 
patients with a BP 140 mmHg systolic and/or 90 mmHg diastolic. Patients in the control 
group received a standard BP booklet and the intervention group used a color-coded booklet for 
daily home BP measurement. The main outcomes were changes in BP, BP control (treatment 
goal 140/90 mmHg), and adherence with home BP measurement after 6 months.
Results: One hundred and twenty-one of 137 included patients qualified for analysis. After 
6 months, a significant decrease in systolic and diastolic BP was achieved in both groups, with 
no significant difference between the groups (16.1/7.9 mmHg in the intervention group versus 
13.1/8.6 mmHg in the control group, P=0.3/0.7). BP control (treatment target 140/90 mmHg) 
was achieved significantly more often in the intervention group (43% versus 25%; P=0.037; 
number needed to treat of 5). Adherence with home BP measurement overall was high, with a 
trend in favor of the intervention group (98.6% versus 96.2%; P=0.1)
Conclusion: Color-coded BP self-monitoring significantly improved BP control (number 
needed to treat of 5, meaning that every fifth patient utilizing color-coded self-monitoring 
achieved better BP control after 6 months), but no significant between-group difference was 
observed in BP change. A markedly higher percentage of patients achieved BP values in the 
normal range. This simple, inexpensive approach of color-coded BP self-monitoring is user-
friendly and applicable in primary care, and should be implemented in the care of patients with 
arterial hypertension.
Keywords: primary care, home blood pressure measurement, hypertension, high blood pres-
sure, general practitioner, number needed to treat
Introduction
Arterial hypertension (AH) is the most common chronic disease among Swiss adults 
apart from dyslipidemia and diabetes mellitus.1 Worldwide, the prevalence of AH among 
adults is estimated to be 26%, representing a major risk factor for cardiovascular morbid-
ity and mortality.2,3 Even though effective medication and guidelines for the treatment 
and management of AH exist,4 the control of high blood pressure (BP) in the community 
is far from optimum.5 In order to reach treatment goals in a chronic condition, adherence 
with treatment and patient collaboration are essential. To successfully cope with and 
manage a chronic disease in the long term it is necessary to acquire skills and to change 
behavior. Home BP measurement (HBPM) is an important skill for patients to monitor 
their disease and has been consistently recommended in  hypertension guidelines.6,7 Yet 
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low adherence with self-monitoring and treatment recom-
mendations remains problematic in daily practice.8 While a 
vast amount of data exist regarding AH and adherence with 
treatment,9–11 relatively few studies and reviews have explored 
how adherence and patient self-monitoring ability can be 
supported and improved, and the conclusions of these stud-
ies are not consistent.12–17 Recommendations for research on 
interventions to improve adherence encourage development 
of interventions that are simple and easily applicable to the 
clinical setting.18 The aim of the Color-coded blood pressure 
Control (CoCo) trial was therefore to analyze the effect of 
a simple, practical tool, ie, a color-coded BP booklet with a 
traffic light scheme for self-monitoring, on BP control and 
adherence with self-measurements. 
Materials and methods 
CoCo is a two-group, randomized controlled trial designed 
to analyze the effect of a color-coded versus usual HBPM 
booklet on adherence with self-monitoring and BP control. 
The detailed study protocol and the baseline characteristics 
of the participating patients and GPs have been previously 
published elsewhere.19,20 The trial is registered under Clini-
calTrials.gov ID NCT01013467.
Sample size
Case number calculation and power analysis were carried out 
on the basis of the expected effect for systolic BP. With an 
alpha of 0.05 and a power of 0.9 (one-sided test), this means 
that 138 patients were required in order to be able to show 
a clinically relevant BP difference of 7 mmHg systolic with 
a standard deviation (SD) of 14 mmHg between the groups. 
Assuming a dropout rate of 20%, this meant that at least 
166 patients were required. Since the dropout rate in our 
population was much lower, we almost managed to reach 
the predefined sample size of 138 patients.
Recruiting and inclusion criteria 
General practitioners (GPs) from the greater area of Zurich 
and St Gallen were invited to consecutively recruit patients 
not or insufficiently treated for AH. Inclusion criteria were: 
age 18 years; BP 140 mmHg systolic and/or 90 mmHg 
diastolic, where the second practice measurement quali-
fied for inclusion; no or unchanged AH treatment for one 
month before inclusion; patient able to perform HBPM; 
and written informed consent. Exclusion criteria were: 
BP 180 mmHg systolic and/or 110 mmHg diastolic (due 
to safety/risk considerations); serious general or psycho-
logical illness, such as malignant tumors, serious depres-
sion, or evidence of dementia; and insufficient knowledge 
of the German language for instruction on BP recordings 
with a booklet. 
Randomization
Randomization took place at the patient level and was per-
formed by the study center. We drew up a randomization list 
by computer (ralloc command of Stata software for Windows, 
version 9). Envelopes containing the patient’s number and 
corresponding booklet were given to the GPs in numerical 
order and distributed by the GP to the patient in order of 
appearance and inclusion.
Measurements
Clinical and demographic data upon inclusion and at 
follow-up were collected by the GPs (Tables 1 and 2). 
Table 1 Patient characteristics at inclusion according to randomization 
Characteristic Intervention group Control group
Number 65 56
Male (%) 53.9 44.6
Age (years) 61.5 (13.1) 62.0 (12.6)
BMI (kg/m2) 28.2 (4.3) 28.8 (5.4)
Smokers (%) 21.5 23.2
Ex-smokers (%) 29.2 28.6
Education (years) 11.4 (4.4) 10.7 (4.1)
Number of AH drugs 1.3 (0.9) 1.6 (1.0)
No AH medication (%) 9.2 12.5
HBPM (%) 61.5 64.3
Systolic BP (mmHg) 157.5 (15.3) 159.5 (13.2) 
Diastolic BP (mmHg) 91.8 (7.6) 92.8 (9.6)
Pulse rate per minute 73.7 (10.3) 75.1 (11.7)
Note: Continuous variables are indicated as the mean and standard deviation.
Abbreviations: AH, arterial hypertension; BMI, body mass index; BP, blood pressure; HBPM, home blood pressure monitoring.
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Patients in the intervention group received the color-coded 
booklet (Figure 1A), with a scheme divided into three mea-
suring zones (green, yellow, red) following a traffic light 
scheme. BP measurements within the target values of up to 
140 mmHg systolic and 90 mmHg diastolic were entered 
into the green area. BP measurements above 140 mmHg 
but below 180 mmHg systolic and/or above 90 mmHg but 
below 110 mmHg diastolic were entered into the yellow 
area, and measurements above 180 mmHg systolic and above 
110 mmHg diastolic in the red area. The colored areas had 
the goal to improve patients’ understanding and interpreta-
tion of BP control by visualizing target and elevated values. 
Pulse rate was also recorded but without any designated color 
coding. Patients in the control group used the usual standard 
booklet (Figure 1B) without color coding. In both booklets, 
the exact time and date of readings were recorded. 
Automatic electronic oscillometric BP measurement 
devices (MioStar Cardioplus 500) for measurement by 
GPs as well as for HBPM were provided to the GP by 
the Institute of General Practice in order to minimize data 
Table 2 Follow-up measurements after 6 months according to randomization 
Criteria Intervention group Control group
Systolic BP (mmHg) 141.4 (13.0) 146.4 (17.9) 
Diastolic BP (mmHg) 83.8 (9.8) 84.2 (11.7) 
BP control (%)* 43.1° 25.0 
Change of systolic BP (mmHg) baseline vs follow-up -16.1 (16.3) -13.1 (16.1) 
Change of diastolic BP (mmHg) baseline vs follow-up -7.9 (9.4) -8.6 (10.4) 
Notes: Continuous variables are indicated as the mean and standard deviation. *BP 140/90 mmHg; °P0.05 between groups.
Abbreviations: BP, blood pressure; vs, versus.
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Figure 1 (A) Color-coded and (B) standard blood pressure booklet. 
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variability through technical differences between devices. 
The device is validated for accuracy of measurement accord-
ing to EU-norm EN1060 and is easy to handle. In order to 
reflect a real life situation, this specific model was chosen 
after previous discussion with GPs on which device is 
mainly used by Swiss patients for HBPM. GPs and patients 
were instructed to perform BP measurements according 
to the guidelines.7,21,22 GPs were instructed to choose an 
appropriate cuff size according to the patient’s upper arm 
circumference. The patients were provided with the device 
and appropriate cuff by the GP at the time of inclusion in 
the study. For baseline BP measurement at the GP office, 
two consecutive BP readings were performed in the seated 
position after a resting period of at least 5 minutes. To rule 
out differences in BP, measurements were performed on both 
arms at baseline. Each subsequent measurement in the GP 
office involved two BP measurements in each case in the left 
arm if the initial measurement did not differ between the two 
arms by more than 5 mmHg. If the measurement differed by 
more than 5 mmHg at baseline, BP was measured at the arm 
with the higher reading subsequently. All the readings were 
recorded, but for inclusion as well as for analysis, the second 
measurement was used. Patients were trained by their GPs in 
correct BP measurement and recording. They also received 
detailed written and illustrated instruction on how to perform 
HBPM. They were instructed to perform BP measurements 
at least every morning, before medication intake, in a seated 
position, after a resting period of at least 5 minutes, on the 
left upper arm with the lower arm resting on the table. Miss-
ing measures were not to be supplemented but entered as a 
dash into the BP booklet. More than one measurement per 
day was allowed; the additional data were not considered 
for analysis concerning adherence to HBPM. Adherence to 
HBPM was defined as the percentage of days with an entry 
of BP measurement during the period of observation. 
The study period was 6 months for both groups. After 
3 and 6 months, a follow-up by the GP took place, where 
clinical parameters and medication changes were recorded. 
The primary endpoint was the difference in systolic 
and diastolic BP readings measured at the practice between 
baseline and after 6 months of follow-up. Secondary 
endpoints were the number of patients who achieved BP 
control 140/90 mmHg at the practice measurement and 
adherence, ie, the absolute number of BP measurements 
(entries in the BP record booklet) by the patients was 
assessed as correlative of adherence during the period of 
observation.
Data processing and ethical approval
The anonymous data forms were sent to the project leaders 
at the Institute of General Practice and the data were entered 
into an Excel database. All patients gave written informed 
consent. The study protocol was approved by the ethics 
committee of Zurich (Kantonale Ethikkommission, Zürich, 
Switzerland, EK-1738).
Statistical analysis
Continuous variables were tested for normality distribution 
by the Shapiro–Wilk test and presented accordingly as the 
median and interquartile range or as the mean and SD, and 
categorical data are presented as frequencies. For categorical 
data, the χ2 test was used to assess treatment group com-
parisons, for continuous variables, comparisons between 
treatment groups were performed via unpaired t-tests. All 
analyses were performed in accordance with the “intention-
to-treat” approach and the latest available measurement was 
used (last observation carried forward). For further analysis 
of the primary and secondary endpoints, we controlled for 
BP levels at baseline and used multilevel regression analysis 
with the GP as the cluster level, thus taking into account that 
patient observations are not independent, ie, observations 
in one cluster tend to be more similar to each other than to 
individuals in the rest of the sample. The amount of cluster-
ing (ie, the variation that is explained by the GP level) was 
assessed by calculating the intraclass correlation coefficient 
(ICC) ranging from 0% (ie, no evidence for clustering) to 
100% (ie, all the variation in BP difference is explained at 
the GP level). The adjusted effect of the booklet on HBPM 
values (weekly averages over 26 weeks) controlled for time 
was analyzed using a multilevel repeated-measures design 
with the patient as the level of clustering. A two-sided alpha 
of 0.05 was set as the level of significance for all compari-
sons. All analyses were calculated using the Stata statistical 
package version 11.2 (Stata Incorporation, College Station, 
TX, USA).
Results 
Study population
The number of participants during the study is depicted in 
the study flow chart (Figure 2). Between October 2009 and 
November 2011, 137 patients were assessed for eligibility by 
30 GPs. Seventy patients were allocated to the intervention 
group, of whom 65 were eligible for analysis, and 67 patients 
were randomized to the control group, of whom 56 were eli-
gible for analysis. Randomization was successful, showing no 
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significant difference in any baseline characteristics between 
the control group and intervention group (Table 1).
Primary endpoint: decrease of systolic 
and diastolic BP after 6 months
Systolic and diastolic BP measurements performed by the 
GP showed a significant decrease after 6 months compared 
with the baseline measurements in both groups, with no 
significant difference in systolic and diastolic BP between 
the groups (Table 2). Mean (SD) systolic BP at baseline 
was 157.5±15.3 mmHg in the intervention group and 
159.5±13.2 mmHg in the control group, and mean diastolic 
BP was 91.8±7.6 mmHg in the intervention group and 
92.8±9.6 mmHg in the control group. Mean (SD) systolic 
BP at follow-up was 141.4±13.0 mmHg in the intervention 
group and 146.4±17.9 mmHg in the control group, and 
mean diastolic BP was 83.8±9.8 mmHg in the intervention 
group and 84.2±11.7 mmHg in the control group. The mean 
decrease in systolic BP showed no benefit of the color-
coded booklet (16.1±16.3 mmHg in the intervention group 
 compared to 13.1±16.1 mmHg in the control group [P=0.3]). 
The mean diastolic BP decrease was 7.9±9.4 mmHg in the 
intervention group and 8.6±10.4 mmHg in the control group 
(P=0.7). The P-values did not significantly change when 
additionally controlled for a GP clustering effect and BP at 
baseline (P=0.123, ICC 6.9% for systolic BP; P=0.848, ICC 
1.8% for diastolic BP). 
Secondary endpoints
Number achieving BP control and adherence 
to HBPM
BP control (140/90 mmHg) was achieved significantly more 
often in the intervention group than in the control group (43.1% 
versus 25.0%; P=0.037, Table 2). The P-value did not change 
when additionally controlled for a GP clustering effect and BP 
at baseline (P=0.044, ICC 16.3%). Adherence was defined as 
the percentage of days with an entry of a BP measurement 
in the booklet. Analysis of measurement frequencies recorded 
in the BP booklets revealed high adherence in both groups, 
with 98.6% completeness for BP measurement recordings in 
the intervention group and 96.2% in the control group, showing 
a trend in favor of the intervention group (P=0.1). 
Enrollment Assessed for eligibility and randomized (n=137)
Lost to follow-up (n=1, not reachable 
for follow-up)
Discontinued intervention (n=1, excluded by 
practice nurse due to malcompliance)
Analyzed (n=65)
♦ Excluded from analysis (n=5)
♦ Not meeting inclusion criteria (n=3, one of 
   which drop out)
♦ Not meeting exclusion criteria (n=2)
Lost to follow-up (n=5, not reachable for 
follow-up)
Discontinued intervention (n=1, did not want 
to measure BP daily)
Analyzed (n=56)
Allocation
Follow-up
Analysis
Allocated to color-coded BP booklet (n=70)
♦ Received allocated intervention (n=70)
♦ Did not receive allocated intervention (n=0)
Allocated to standard BP booklet (n=67)
♦ Received allocated intervention (n=67)
♦ Did not receive allocated intervention (n=0)
♦ Excluded from analysis (n=11)
♦Not meeting inclusion criteria (n=8)
♦Not meeting exclusion criteria (n=3)
Figure 2 Study flow chart.
Abbreviation: BP, blood pressure.
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Home BP measurements 
Analysis of weekly averages for HBPM values recorded in 
the booklets over 26 weeks showed a significant influence 
of color coding on systolic BP adjusted for time; using a 
color-coded booklet was independently associated with 
reduced systolic BP (regression coefficient -4.26, 95% con-
fidence interval [CI] -7.85, -0.68; P=0.020). No significant 
 association with diastolic BP was found (regression coef-
ficient -1.03, 95% CI -4.22, 2.15; P=0.53). 
Antihypertensive medication 
At the time of inclusion in the study, 108 patients (89.3%) 
received AH treatment, of which 38.8% had monotherapy, 
30.6% had dual therapy, and the remaining 19.8% took 
three or more AH drugs. No difference in distribution of 
AH therapy concerning number of AH drugs (P=0.2831) 
was found between the two groups. The most commonly 
prescribed AH substances were diuretics (38.8%) and 
angiotensin-converting enzyme (ACE) inhibitors (36.4%), 
followed by angiotensin receptor type 2 (AT2) inhibitors 
(29.8%). Concerning the distribution of AH substances, no 
difference between the groups existed, except for the control 
group being treated more often with ACE inhibitors when 
compared with the intervention group (P=0.012). 
At follow-up after 6 months, the proportion of patients 
without AH treatment had decreased from 10.7% to 3.5%, 
with 21.2% receiving monotherapy, 30.1% dual therapy, and 
45.1% three or more AH drugs. No difference in distribution 
concerning number of AH drugs was found between the 
two groups (P=0.1971). Overall, in 63% of patients, the AH 
therapy was changed (68.1% of the control group and 59.7% 
of the intervention group). No difference existed in overall 
change of AH therapy between the groups (P=0.367 for any 
alteration of dosage of any AH substance and/or amount of 
substances). 
The most commonly prescribed AH drugs were diuretics 
(60.5%) and AT2 inhibitors (56.1%), followed by ACE inhib-
itors (47.3%). Concerning the distribution of AH substances, 
no difference between the groups existed except for the inter-
vention group being treated more often with AT2 inhibitors 
when compared with the control group (P=0.007). 
Participating GPs
Detailed characteristics on the 30 participating GPs have been 
reported previously.19 No difference could be found between 
the control group and the intervention group concerning 
the following GP characteristics: geographic distribution 
(urban, suburban, or rural), specialization (internal or general 
medicine), age, practice experience, time since completion of 
board examination, employment (part-time or full-time), and 
use of and time since implementation of electronic patient 
records. A significant difference between the groups was 
found with regard to the following GP characteristics: in 
the intervention group more GPs were male (39 versus 43, 
P=0.0336) and more worked in groups rather than single-
handed practices (36 versus 40, P=0.0113). 
Discussion
BP control, defined as the proportion of BP values within 
normal range, significantly improved in patients using 
the color-coded BP monitoring booklet. The absolute BP 
reduction did not differ between the groups and adherence 
with HBPM was high in both groups, with a trend in favor 
of the color-coded booklet. The effect of color-coded self-
monitoring on BP control can be translated in a number 
needed to treat of 5, meaning that every fifth patient utiliz-
ing color-coded self-monitoring achieves better BP control 
after 6 months.
Various studies have shown that BP control is far below 
the optimum and treatment goals are achieved in currently 
half of the patients who are treated for AH.23 Important ele-
ments associated with improved BP control are a rigorous 
stepped-care approach to AH drug treatment, organization 
of care with regular follow-up, and interventions and moti-
vational strategies that aim to help patients achieve better 
medication use and BP management.24 HBPM is one of 
these supportive measures. Randomized controlled trials 
have shown that self-monitoring of BP results in better BP 
control.8,25,26 A recently published meta-analysis showed 
that HBMP alone was able to reduce BP over 6 months but 
not in the long term (more than 12 months). In patients with 
HBPM and additional support, the effect on long-term BP 
reduction was significantly improved.27 
The rationale for color-coded BP monitoring was to moti-
vate patients to self-monitor and to facilitate interpretation 
by visualized information with a traffic light system and thus 
trigger appropriate behavior. The concept behind such tools 
aiming to improve adherence and disease control is self-
regulation. Self-regulation is meant to support the patient’s 
perception and capability for decision-making and to help 
them to develop strategies and health behavior associated 
with better outcomes.28,29 
To our knowledge, this is the first paper assessing the 
effect of color-coded self-monitoring without self-titration 
on BP control. Earlier studies comparing a patient-directed 
management strategy with office-based management in 
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primary care used HBPM with an algorithm for upward and 
downward adjustments of drug therapy, but not a color traf-
fic light algorithm.30 TASMINH2 (the Telemonitoring and 
Self-Management of Hypertension Trial) consisted of self-
monitoring of BP combined with telemonitoring by means 
of an automated modem device that was connected to a 
sphygmomanometer and self-titration of AH drugs according 
to a color traffic light system comparable with our scheme to 
code the BP readings.31 The primary endpoint was change in 
mean systolic BP. Mean systolic BP decreased by 12.9 mmHg 
(95% CI 10.4–15.5) from baseline to 6 months in the self-
management group and by 9.2 mmHg (95% CI 6.7–11.8) in 
the control group (difference between groups 3.7 mmHg, 95% 
CI 0.8–6.6; P=0.013) which is comparable with our results. 
Several factors can explain why only a trend in benefit 
of the color-coded self-monitoring on BP reduction could be 
found in our study, although BP control as well as systolic 
values in HBPM showed a significant improvement in the 
group with the color-coded booklet. A Hawthorne and/or 
regression to the mean effect seems likely when consid-
ering the very significant systolic (approximately 13 and 
16 mmHg) and diastolic (approximately 8 mmHg) BP 
decrease achieved in both groups, even though two thirds 
of patients already performed HBPM before inclusion in the 
study. The study was designed to estimate the effect over a 
period of 6 months. It is possible that the effect of color-coded 
monitoring might have increased after a longer time period. 
The most likely reason is that, unlike the TASMINH2 study, 
no action plan was tied to the color-coding. It has been shown 
for several chronic illnesses that self-management consisting 
of regular self-measurements and a written action plan for 
adjusting treatment is more effective than care without an 
action plan.31–36 We almost reached the prespecified sample 
size, suggesting a lack of power or type 2 error as a pos-
sible explanation for not reaching significance concerning 
BP reduction, although significance for BP control as well 
as systolic BP in HBPM was achieved. Lack of blinding of 
participating GPs and patients to intervention might have 
biased the results as well. 
In our study, patients were instructed to perform HBPM 
every morning before medication intake. No evening or 
daytime measurements were required by the protocol, as 
suggested in the guidelines.7,22 It was left to the discretion 
of the patient whether to perform additional measurements. 
It is clear that a whole day reflects BP control more in detail. 
We chose this simple protocol to reflect the real life situation, 
since it is not realistic to demand that patients perform an 
all-day protocol during a 6-month period. The study endpoint 
was change in BP measured at the GP’s office and adherence 
to HBPM, not change in HBPM values; therefore, it was not 
necessary to analyze the whole day HBPM profile. The color-
coded BP booklet aimed at triggering behavioral change in 
the event of BP measurements beyond target, possibly result-
ing in altered patient-GP interaction and treatment adapta-
tion. Hence it was not necessary to demand a more rigorous 
measuring protocol for HBPM. On the contrary, by requiring 
more HBPM measurements throughout the day, the intuitive 
effect of the color-coded booklet might have been antici-
pated by a rigorous study protocol. These considerations are 
reflected in the finding that many patients with HBPM values 
out of target performed additional measurements throughout 
the day because of their own motivation.
In our study, remarkable BP control as well as improved 
systolic BP in HBPM was achieved with color-coded self-
monitoring. The study did not assess the exact mechanisms 
of how the color-coded booklet managed to improve BP con-
trol when compared with the standard booklet. The detailed 
processes on the part of the patient and doctor as well as the 
interaction between the two remain a black box and offer 
interesting aspects to be studied further in daily practice. The 
booklet only offers a “surrogate” for many possible mecha-
nisms leading to improved BP control. Since no difference in 
change of AH therapy between the groups was found in our 
study, this suggests that the effect of the color-coding can not 
only be reduced to medication change performed by the GP. 
The color-coding probably mediates lifestyle changes and 
better adherence to treatment in addition to alerting the GP 
to make medication changes when needed. The data reported 
by McManus et al31 showed that 70% of patients who self-
managed their hypertension made at least one medication 
change. We can only assume that the better visualization of 
BP ranges in the color-coded booklet led to some form of 
self-management in patients and probably also better patient–
doctor communication. The potential role of physicians in 
BP control and their behavioral change (beyond changes in 
prescriptions) was not addressed in our study. However, there 
is published work regarding the effect of self-monitoring 
itself demonstrating a positive effect on BP.16 In our study, 
we observed high levels of adherence with self-monitoring 
in both groups. A direct association between adherence to 
HBPM and BP control can therefore not be postulated. This 
puts emphasis on the color-coding with respect to BP control 
and might reflect that people need support in the interpre-
tation of risk and that simple interpretation aids work and 
have the potential to induce healthy behavior. Even though 
there was a shift in use of AH substances from the baseline 
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(more ACE inhibitors in the control group) to follow-up 
(more AT2 inhibitors in the intervention group), the overall 
escalation of therapy concerning number of AH drugs and 
substance distribution otherwise did not differ between the 
groups. Improved BP control therefore cannot be explained 
by an intensified step-up approach of AH drugs alone, and 
the color coding seems to have additional effects. 
Strengths and limitations
There are several shortcomings to be mentioned. Along with 
the study information, the GPs received a list and instructions 
to register all patients they asked to participate and all patients 
who declined to participate. This list was unfortunately not 
completed by the majority of GPs, so it is unknown how 
many of the potentially eligible patients were included in 
the trial. The objective of the present study was to assess the 
effectiveness of a simple intervention aimed at improving 
BP control. Information that might possibly influence BP 
control, such as renal function, hyperaldosteronism, and BP-
influencing medications, such as non-steroidal antirheumatic 
drugs or systemic corticosteroids, was not collected. How-
ever, randomization was successful, showing no significant 
difference in baseline characteristics between the groups. It 
therefore seems justified to assume that comorbidities were 
also equally distributed. Statements concerning conformity 
of the prescribed AH treatments with the guidelines are not 
possible since comorbidities and drug intolerances were 
not recorded in the study data. In our study, adherence to 
treatment was not evaluated, but BP measurement was used 
as a surrogate for adherence. Nevertheless, we assume that 
patients willing to participate in the study, perform daily BP 
measurements, and enter them into a booklet are likely to 
comply with therapy. No HBPM measurement at baseline 
was available. We chose practice measures for primary and 
secondary outcomes due to their reproducibility. HBPM 
was only assessed after inclusion into the study. The BP 
measurement device was chosen according to its popularity 
in our study population and its practicality in usage. It is 
validated according to EU-norm EN1060, but it is uncertain 
whether it would pass the validation process of the European 
Society of Hypertension International Protocol.7,37 Since all 
participating GPs and patients received the same device, 
possible flaws in measurement accuracy were equalized 
through randomization of the study population. The device 
used in our study only offers a memory function for the last 
measured value. It was therefore not possible to check for 
the reliability of measurements recorded by patients in their 
booklets. The primary and secondary outcomes consisted of 
practice measurements performed by the GP that made the 
information on correctness of entries less relevant for the 
study outcome.
The strength of our study is that it offers a view on “real 
life” primary care patients, with uncontrolled AH in 90% 
of those on AH treatment at the time of inclusion into the 
study. Further, the low intensity and low complexity of the 
intervention makes it applicable for primary care, where AH 
is largely managed. GPs and patients are already used to 
and are using booklets for BP monitoring in daily practice. 
Therefore, our intervention adding only a color-coded traf-
fic light scheme avoided the substantial extra effort which 
is often feasible under study conditions but not in practice 
over a longer time period. 
Perspectives
While there is a strong evidence base for the benefits of AH 
drug therapy, there is less clear evidence for supplementary 
care, including self- monitoring of BP by patients. Our study 
results support color-coded self-monitoring using a traffic 
light scheme as a useful, simple, inexpensive, and applicable 
adjunct to care for people with AH. This is important in 
light of the fact that self-monitoring is now widely prac-
ticed. By means of emerging computerized monitoring, it 
will be possible to implement individualized color coding 
according to preferred BP targets. Color coding is an effec-
tive intervention that improves BP control; however, the 
relationship between control of BP, self-monitoring, and 
self-management interventions needs further evaluation 
with quantitative as well as qualitative research. Addition-
ally, evaluation of effect in larger, long-term, randomized 
controlled trials of cardiovascular morbidity and mortality 
is required. 
Conclusion
Color-coded BP self-monitoring significantly improved 
BP control (number needed to treat of 5), but no significant 
between-group difference was observed in BP change. 
A remarkable higher percentage of patients achieved BP 
values in the normal range. This inexpensive, simple method 
of color-coded BP self-monitoring is easily applicable and 
feasible in primary care, and should be implemented in care 
for patients with AH.
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